News

Article

Catalent Closes Acquisition of Paragon Bioservices

Catalent expands gene therapy capabilities with $1.2-billion acquisition of Paragon Bioservices.

Catalent, Inc. announced on May 20, 2019 the completion of a $1.2-billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing company for gene therapies with expertise in adeno-associated virus vectors. Paragon’s capabilities will enhance Catalent’s biologics business and integrated biopharmaceutical solutions for customers, Catalent reported in a press statement announcing the close of the sale.

Paragon is working on GMP manufacturing projects with more than half of the top 40 leading gene therapy developers worldwide, according to the statement. The company recently opened a commercial manufacturing center near the Baltimore-Washington International airport, which is equipped with several 500-L and 2000-L single-use bioreactors for clinical through commercial material production. The production campus-combined with a leased second building that will be built out for commercial GMP manufacturing-has the potential for more than 425,000-sq.ft. of manufacturing space upon completion, Catalent reports.

Source: Catalent Pharma Solutions

 

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content